StimCardio's NeuroPulse Study Reports Substantial Reduction in Recurrent Atrial Fibrillation Events Via Non-Invasive Wearable Neuromodulation Following Ablation

Data ReadoutpositiveNeuroPulsePositive

AI Analysis

Summary

StimCardio's NeuroPulse non-invasive wearable neuromodulation device demonstrated 90% freedom from atrial arrhythmias at six months versus 80.8% with sham in a randomized, double-blind, sham-controlled trial presented at HRX Live 2026.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

90% freedom from atrial arrhythmias at six months with neuromodulation vs. 80.8% with sham in randomized, double-blind, sham-controlled trial

Importance:6/10

Sentiment:

0.85

atrial fibrillationneuromodulationwearableclinical triallate-breaking datarandomized controlled trial

Related Companies

$WHSI

Read the original article

Published by PR Newswire Pharma on September 20, 2026 3:00 PM

Read Original